Bullish & Foolish
Full CUE fundamentals All 466 on the Survival Watch

CUECue Biopharma, Inc.

Is Cue Biopharma struggling financially?

Yes, by its own account. Cue Biopharma told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Needs to raise money

    We will need to raise additional capital or incur additional indebtedness to continue to fund our operations in the near term.

    Form 10-Q, filed 14 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$174.2M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$17.4M

÷

Cash burned over the last 12 months

$73.0M

What Cue Biopharma told the SEC

…are made in this report could be materially different from those anticipated in such forward-looking statements. Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern. Company management has obtained and continues to pursue additional financing and cost-management initiatives to support future operations, however such funding may not be available on…

Cue Biopharma, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is increasing It is spending 29% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt